ABBV.BA

AbbVie Inc. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of a wide array of pharmaceutical products. The company's diverse portfolio includes leading therapies such as Humira, an injectable medication used for a range of autoimmune and inflammatory conditions like intestinal Behçet's disease and pyoderma gangrenosum. They also offer Skyrizi, targeting moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn's disease, and Rinvoq, a JAK inhibitor effective against rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis. In the field of oncology, AbbVie provides Imbruvica for the treatment of various adult blood cancers, along with Venclexta/Venclyxto, which addresses hematological malignancies. Beyond pharmaceuticals, their offerings extend to aesthetic products, including facial injectables, plastics and regenerative medicine, body contouring solutions, and skincare. Their neuroscience pipeline features Vraylar for depressive disorder, Duopa and Duodopa for advanced Parkinson's disease, and specialized migraine treatments such as Ubrelvy for acute relief and Qulipta for episodic migraine prevention. For ophthalmologic conditions, the company produces Lumigan/Ganfort and Alphagan/Combigan to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Restasis, an immunosuppressant, is also available to boost tear production, complemented by other comprehensive eye care solutions. Furthermore, AbbVie markets Mavyret/Maviret for chronic hepatitis C virus infections across multiple genotypes, Creon as a pancreatic enzyme replacement therapy, and Lupron for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia linked to uterine fibroids. Linzess/Constella is provided for irritable bowel syndrome with constipation and chronic idiopathic constipation, while Synthroid manages hypothyroidism. AbbVie actively engages in strategic alliances, collaborating with entities such as Calico Life Sciences LLC, REGENXBIO Inc., I-Mab Biopharma, Genmab A/S, Janssen Biotech, Inc., Genentech, Inc., and the California Institute for Biomedical Research (Calibr). The company was established in 2012 and is headquartered in North Chicago, Illinois.